• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

内源性阿片肽系统不参与调节阿片类药物引起的痛觉过敏。

The endogenous opioid system is not involved in modulation of opioid-induced hyperalgesia.

机构信息

Department of Anesthesia, Stanford University School of Medicine, 300 Pasteur Drive, Stanford, CA 94305, USA.

出版信息

J Pain. 2011 Jan;12(1):108-15. doi: 10.1016/j.jpain.2010.05.006.

DOI:10.1016/j.jpain.2010.05.006
PMID:20864417
Abstract

UNLABELLED

Some recent studies suggested a role of the endogenous opioid system in modulating opioid-induced hyperalgesia (OIH). In order to test this hypothesis, we conducted a prospective randomized, placebo-controlled, 2-way crossover study in healthy human volunteers. We utilized a well-established model of inducing OIH after a brief exposure to the μ-opioid agonist remifentanil using intradermal electrical stimulation. Patients were exposed to a randomized 90-minute infusion of remifentanil or saline placebo during 2 separate occasions. Development of OIH was quantified using changes in the average radius of the area of secondary hyperalgesia generated by electrical pain stimulation. A 23.6% (20.2) increase in area of secondary hyperalgesia over baseline was observed in the postinfusion period of the remifentanil session, demonstrating development of OIH (P = .03). In order to test endogenous opioid system modulation of OIH, patients were given a 1-time bolus of naloxone, which had no effect on the size of the hyperalgesic lesion in either the remifentinal or placebo session. These results suggested that the endogenous opioid system did not appear to modulate OIH.

PERSPECTIVE

Experimental evidence suggested that the endogenous opioid system did not significantly affect opioid-induced hyperalgesia. Consequently, this study suggested that alternative mechanisms such as pronociceptive stimulation and neuroplastic changes might be responsible for expression of OIH.

摘要

未加标签

一些最近的研究表明,内源性阿片系统在调节阿片类药物引起的痛觉过敏(OIH)中起作用。为了验证这一假设,我们在健康的人类志愿者中进行了一项前瞻性随机、安慰剂对照、2 向交叉研究。我们利用一种经过充分验证的模型,即在短暂暴露于μ阿片受体激动剂瑞芬太尼后,通过皮内电刺激来诱导 OIH。患者在 2 次单独的情况下接受随机 90 分钟的瑞芬太尼或盐水安慰剂输注。使用电疼痛刺激产生的继发性超敏反应区域的平均半径变化来量化 OIH 的发展。在瑞芬太尼输注后的输注期,观察到继发性超敏反应区域增加了 23.6%(20.2),表明发生了 OIH(P=0.03)。为了测试内源性阿片系统对 OIH 的调节作用,患者给予单次纳洛酮推注,纳洛酮对瑞芬太尼或安慰剂输注期的痛觉过敏病变大小均无影响。这些结果表明,内源性阿片系统似乎没有调节 OIH。

观点

实验证据表明,内源性阿片系统对阿片类药物引起的痛觉过敏没有显著影响。因此,本研究表明,替代机制,如促伤害性刺激和神经可塑性变化,可能是 OIH 表达的原因。

相似文献

1
The endogenous opioid system is not involved in modulation of opioid-induced hyperalgesia.内源性阿片肽系统不参与调节阿片类药物引起的痛觉过敏。
J Pain. 2011 Jan;12(1):108-15. doi: 10.1016/j.jpain.2010.05.006.
2
Gradual withdrawal of remifentanil infusion may prevent opioid-induced hyperalgesia.瑞芬太尼输注的逐渐停药可能预防阿片类药物诱发的痛觉过敏。
Br J Anaesth. 2016 Apr;116(4):524-30. doi: 10.1093/bja/aev547. Epub 2016 Mar 1.
3
Effects of COX inhibition on experimental pain and hyperalgesia during and after remifentanil infusion in humans.COX 抑制对瑞芬太尼输注期间和输注后人体实验性疼痛和痛觉过敏的影响。
Pain. 2011 Jun;152(6):1289-1297. doi: 10.1016/j.pain.2011.02.007. Epub 2011 Mar 10.
4
Differential modulation of remifentanil-induced analgesia and postinfusion hyperalgesia by S-ketamine and clonidine in humans.S-氯胺酮和可乐定对瑞芬太尼诱导的镇痛和输注后痛觉过敏的差异调节作用(人体研究)
Anesthesiology. 2003 Jul;99(1):152-9. doi: 10.1097/00000542-200307000-00025.
5
A comprehensive review of opioid-induced hyperalgesia.阿片类药物诱导痛觉过敏的综合评价。
Pain Physician. 2011 Mar-Apr;14(2):145-61.
6
Effect of a high-dose target-controlled naloxone infusion on pain and hyperalgesia in patients following groin hernia repair: study protocol for a randomized controlled trial.高剂量靶控输注纳洛酮对腹股沟疝修补术后患者疼痛和痛觉过敏的影响:一项随机对照试验的研究方案
Trials. 2015 Nov 10;16:511. doi: 10.1186/s13063-015-1021-6.
7
Dexmedetomidine prevents remifentanil-induced postoperative hyperalgesia and decreases spinal tyrosine phosphorylation of N-methyl-d-aspartate receptor 2B subunit.右美托咪定预防瑞芬太尼引起的术后痛觉过敏,并降低脊髓 N-甲基-D-天冬氨酸受体 2B 亚基酪氨酸磷酸化。
Brain Res Bull. 2012 Mar 10;87(4-5):427-31. doi: 10.1016/j.brainresbull.2012.01.009. Epub 2012 Jan 25.
8
Modulation of remifentanil-induced postinfusion hyperalgesia by propofol.丙泊酚对瑞芬太尼输注后痛觉过敏的调节作用。
Anesth Analg. 2007 Jun;104(6):1397-403, table of contents. doi: 10.1213/01.ane.0000261305.22324.f3.
9
Effects of naloxone on opioid-induced hyperalgesia and tolerance to remifentanil under sevoflurane anesthesia in rats.纳洛酮对七氟醚麻醉下瑞芬太尼引起的阿片类药物痛觉过敏和耐受的影响。
Anesthesiology. 2013 May;118(5):1160-9. doi: 10.1097/ALN.0b013e3182887526.
10
Naloxone provokes similar pain facilitation as observed after short-term infusion of remifentanil in humans.纳洛酮引发的疼痛易化作用与人类短期输注瑞芬太尼后观察到的相似。
Pain. 2003 Nov;106(1-2):91-9. doi: 10.1016/s0304-3959(03)00294-x.

引用本文的文献

1
A systematic review and meta-analysis of pharmacological methods to manipulate experimentally induced secondary hypersensitivity.对用于操控实验性诱导的继发性超敏反应的药理学方法的系统评价和荟萃分析。
Pain. 2025 Apr 15;166(9):2008-2023. doi: 10.1097/j.pain.0000000000003568.
2
Reflecting on Cancer Pain as Constant Acute Pain, not Chronic Pain. 'Known Knowns, Known Unknowns, Unknown Unknowns'.将癌症疼痛视为持续性急性疼痛而非慢性疼痛。“已知的已知、已知的未知、未知的未知”。
Curr Oncol Rep. 2025 May;27(5):584-600. doi: 10.1007/s11912-025-01642-w. Epub 2025 Apr 3.
3
Remifentanil-induced hyperalgesia in healthy volunteers: a systematic review and meta-analysis of randomized controlled trials.
瑞芬太尼诱导健康志愿者痛觉过敏:随机对照试验的系统评价和荟萃分析。
Pain. 2024 May 1;165(5):972-982. doi: 10.1097/j.pain.0000000000003119. Epub 2023 Nov 30.
4
Wnt3a Inhibitor Attenuates Remifentanil-Induced Hyperalgesia via Downregulating Spinal NMDA Receptor in Rats.Wnt3a抑制剂通过下调大鼠脊髓N-甲基-D-天冬氨酸受体减轻瑞芬太尼诱导的痛觉过敏
J Pain Res. 2020 May 19;13:1049-1058. doi: 10.2147/JPR.S250663. eCollection 2020.
5
Transcranial Direct Current Stimulation to Improve the Dysfunction of Descending Pain Modulatory System Related to Opioids in Chronic Non-cancer Pain: An Integrative Review of Neurobiology and Meta-Analysis.经颅直流电刺激改善慢性非癌性疼痛中与阿片类药物相关的下行疼痛调制系统功能障碍:神经生物学与荟萃分析的综合综述
Front Neurosci. 2019 Nov 18;13:1218. doi: 10.3389/fnins.2019.01218. eCollection 2019.
6
Opioid-induced myoclonus and hyperalgesia following a short course of low-dose oral morphine.小剂量口服吗啡短期治疗后出现阿片类药物诱发的肌阵挛和痛觉过敏。
Br J Pain. 2017 Feb;11(1):32-35. doi: 10.1177/2049463716664371. Epub 2016 Aug 22.
7
Cancer pain physiology.癌症疼痛生理学。
Br J Pain. 2014 Nov;8(4):154-62. doi: 10.1177/2049463714545136.
8
Endogenous opioid antagonism in physiological experimental pain models: a systematic review.生理实验性疼痛模型中的内源性阿片拮抗作用:一项系统评价。
PLoS One. 2015 Jun 1;10(6):e0125887. doi: 10.1371/journal.pone.0125887. eCollection 2015.
9
Therapeutic Basis of Clinical Pain Modulation.临床疼痛调制的治疗基础。
Clin Transl Sci. 2015 Dec;8(6):848-56. doi: 10.1111/cts.12282. Epub 2015 May 11.
10
Inhibition of glycogen synthase kinase-3β prevents remifentanil-induced hyperalgesia via regulating the expression and function of spinal N-methyl-D-aspartate receptors in vivo and vitro.体内和体外研究显示,抑制糖原合酶激酶-3β可通过调节脊髓 N-甲基-D-天冬氨酸受体的表达和功能预防瑞芬太尼诱发的痛觉过敏。
PLoS One. 2013 Oct 16;8(10):e77790. doi: 10.1371/journal.pone.0077790. eCollection 2013.